EyeGate opens doors to interested partner, buyer
This article was originally published in Clinica
Executive Summary
Ophthalmic drug delivery specialist EyeGate Pharma reported that EGP-437 (dexamethasone) administered via iontophoresis achieved the same response rate as the standard of care for patients with anterior uveitis in a Phase III clinical trial.